- Home
- FMAO vs FATE Comparison
FMAO vs FATE Comparison
Compare FMAO & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- FATE
- Stock Information
- Founded
- FMAO 1897
- FATE 2007
- Country
- FMAO United States
- FATE United States
- Employees
- FMAO N/A
- FATE N/A
- Industry
- FMAO Savings Institutions
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FMAO Finance
- FATE Health Care
- Exchange
- FMAO Nasdaq
- FATE Nasdaq
- Market Cap
- FMAO 377.5M
- FATE 406.5M
- IPO Year
- FMAO N/A
- FATE 2013
- Fundamental
- Price
- FMAO $29.92
- FATE $1.68
- Analyst Decision
- FMAO Hold
- FATE Hold
- Analyst Count
- FMAO 2
- FATE 10
- Target Price
- FMAO $26.00
- FATE $6.75
- AVG Volume (30 Days)
- FMAO 24.1K
- FATE 4.4M
- Earning Date
- FMAO 02-11-2025
- FATE 11-12-2024
- Dividend Yield
- FMAO 2.96%
- FATE N/A
- EPS Growth
- FMAO N/A
- FATE N/A
- EPS
- FMAO 1.69
- FATE N/A
- Revenue
- FMAO $98,003,000.00
- FATE $13,447,000.00
- Revenue This Year
- FMAO N/A
- FATE N/A
- Revenue Next Year
- FMAO $8.16
- FATE N/A
- P/E Ratio
- FMAO $17.71
- FATE N/A
- Revenue Growth
- FMAO N/A
- FATE N/A
- 52 Week Low
- FMAO $18.99
- FATE $1.59
- 52 Week High
- FMAO $34.15
- FATE $8.83
- Technical
- Relative Strength Index (RSI)
- FMAO 39.11
- FATE 35.65
- Support Level
- FMAO $31.70
- FATE $1.59
- Resistance Level
- FMAO $33.02
- FATE $2.07
- Average True Range (ATR)
- FMAO 1.03
- FATE 0.25
- MACD
- FMAO -0.51
- FATE -0.08
- Stochastic Oscillator
- FMAO 21.04
- FATE 6.47
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company for Farmers & Merchants Bank of Central California. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.